BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint
BOAN BIOTECH (06955) announced that the Phase III clinical trial in China of the company's PD-1 inhibitor BA1104 (nivolumab injection) has been completed and met the primary endpoint. The company will soon submit a marketing authorization application for this product to China's National Medical Products Administration (NMPA). BA1104 is the first Opdivo biosimilar in China to complete a Phase III clinical trial. In accordance with the "Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars," the company intends to apply for the indications approved for Opdivo in China.
BOAN BIOTECH (06955) announced that the China Phase III clinical trial of the company's PD-1 inhibitor BA1104 (nivolumab injection) has been completed and met the primary endpoint. The company will soon submit a marketing authorization application for this product to China's National Medical Products Administration (NMPA). BA1104 is the first biosimilar of Opdivo in China to complete a Phase III clinical trial. In accordance with the "Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilars," the company intends to apply for the indications approved for Opdivo in China.
Nivolumab is a humanized monoclonal antibody (IgG4 subtype) targeting the programmed cell death 1 (PD-1) receptor. By blocking the binding of the PD-1 receptor to its ligands PD-L1 and PD-L2, it enhances the anti-tumor response of T cells and is a cornerstone drug in tumor immunotherapy. Public information shows that Opdivo has been approved for multiple indications in dozens of countries and regions worldwide, covering multiple tumor types, and its clinical application spans all stages of tumor treatment, including preoperative neoadjuvant therapy, postoperative adjuvant therapy, and first-line and later-line treatment of advanced tumors, with administration methods including monotherapy, combination with chemotherapy, and combination with new immune checkpoint inhibitors. In 2025, global sales revenue of Opdivo reached US$10.049 billion, up 8% year on year.
BA1104 was developed in accordance with the biosimilar research guidelines of China, the United States, Europe, and Japan. This Phase III clinical trial was a randomized, double-blind, multicenter clinical study designed to compare the efficacy and safety of BA1104 versus Opdivo, each in combination with chemotherapy, in patients with advanced or metastatic esophageal squamous cell carcinoma.
The Phase III clinical study met the prespecified primary endpoint. The study results showed that the confidence interval of the objective response rate (ORR) ratio between BA1104 and the reference product fell entirely within the prespecified equivalence margin, demonstrating equivalence between the two. The results of independent central imaging assessment were in good agreement with those of investigator assessment. Secondary efficacy endpoints included disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), among others; the results in the two groups were highly similar, and no clinically meaningful difference in efficacy was observed. In terms of safety, BA1104 demonstrated good overall safety and tolerability, and the two were highly similar in safety. The positive rates of anti-drug antibodies (ADA) and neutralizing antibodies (NAb) were low and similar in both groups, indicating similar immunogenicity between the two.
Previously, BA1104 had completed pharmaceutical and non-clinical comparability studies with Opdivo, and a randomized, double-blind, single-dose Phase I clinical study was conducted in healthy Chinese male volunteers to evaluate the pharmacokinetic (PK) characteristics, safety, and immunogenicity of the two. The 90% confidence intervals of AUC0-, AUC0-t, and Cmax for BA1104 and the reference product all fell within the prespecified range of 80.00%-125.00%, confirming that the PK characteristics of the two are highly similar. The results of this study have been published in the international journal BioDrugs. In the Phase I clinical study, the ADA and NAb positive rates were comparable between the two, with similar immunogenicity.
In addition to China, the company is also actively expanding the overseas layout of BA1104. Previously, the company completed a biosimilar biological product development (BPD) Type 2b meeting communication with the U.S. Food and Drug Administration (FDA). The FDA agreed to a "streamlined" clinical development strategy under which only one PK similarity study (Phase I trial) is required to submit a biologics license application (BLA), without the need for a Phase III clinical trial. In addition, the company plans to carry out registration and marketing work for BA1104 in more countries and regions.
PD-1 inhibitors are currently cornerstone drugs in the field of tumor immunotherapy. Beyond the development of BA1104 as a biosimilar, the company is also actively exploring the therapeutic potential of combining it with its own innovative antibodies. With a development strategy of "immuno-oncology + antibody-drug conjugate (IO+ADC)," the company is building a differentiated innovative pipeline and exploring innovative regimens that balance efficacy and safety and more effectively address drug resistance, with the aim of driving new breakthroughs in tumor treatment.
Related Articles

LEADS BIOLABS-B (09887): Trustee purchases 220,700 H shares under the H-share award scheme
CARRY WEALTH (00643) clarifies that Hu Dongmei has not become and is not a director of the company.

Deshi Technology (02526) is about to globally debut the upgraded iMedLoop, connecting the "personal + clinical + research" three entry points for the first time.
LEADS BIOLABS-B (09887): Trustee purchases 220,700 H shares under the H-share award scheme

CARRY WEALTH (00643) clarifies that Hu Dongmei has not become and is not a director of the company.
Deshi Technology (02526) is about to globally debut the upgraded iMedLoop, connecting the "personal + clinical + research" three entry points for the first time.






